Growth Hormone Administration to Improve Reproductive Outcomes in Women with Recurrent Implantation Failure (RIF): a Systematic Review.


Journal

Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249

Informations de publication

Date de publication:
06 2023
Historique:
received: 16 08 2022
accepted: 05 11 2022
medline: 1 6 2023
pubmed: 6 12 2022
entrez: 5 12 2022
Statut: ppublish

Résumé

Recurrent implantation failure (RIF) has been used to describe embryos' failure to implant following IVF, arising concerns about the importance of its treatment. Growth hormone (GH) has been studied as one of the possible co-interventions. Our updated review evaluated GH intervention vs. no intervention from randomized controlled trials (RCTs) in RIF patients. Electronic searches on The Menstrual Disorders and Subfertility Group (MDSG), The Cochrane Central Register for Clinical Trials, PubMed MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS, and Google Scholar up to August 2021 identified 2 RCTs and compiled with the above inclusion criteria. The risk of bias (ROB) and the quality of evidence were assessed according to the Cochrane Collaboration tool and GRADE group guidelines. Meta-analysis found higher rates of clinical pregnancy (OR: 4.97 CI 95% 2.05 to 12.05), live birth (OR: 5.13 CI 95% 2.03 to 12.91), and implantation (OR: 3.88 CI 95% 1.91 to 7.88) when compared GH to no intervention; as well as an increased endometrial thickness (mean difference: 1.14 CI 95% -0.0 to 2.28). However, this review cannot provide a strong recommendation due to the quality of evidence rated as "very low quality of evidence" in all the outcomes for reasons such as methodology issues, heterogeneity, intervention regimen, and limited sample sizes with large confidence intervals and a low number of events. We emphasize the importance of upcoming high-quality research and the need for consensus concepts in RIF patients, which may be a minority; it is still one of the highest impacts on life quality.

Identifiants

pubmed: 36471218
doi: 10.1007/s43032-022-01124-5
pii: 10.1007/s43032-022-01124-5
doi:

Substances chimiques

Growth Hormone 9002-72-6

Types de publication

Systematic Review Meta-Analysis Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1712-1723

Informations de copyright

© 2022. The Author(s), under exclusive licence to Society for Reproductive Investigation.

Références

Ochoa-Bernal M, Fazleabas A. Physiologic events of embryo implantation and decidualization in human and non-human primates. Int J Mol Sci. 2020;21(6):1973–94.
pubmed: 32183093 pmcid: 7139778 doi: 10.3390/ijms21061973
Robins JC. Implantation: trophoblast-endometrial interactions. Semin Reprod Med. 2016;34(1):3–4.
pubmed: 26731466 doi: 10.1055/s-0035-1570034
Kim S, Kim J. A review of mechanisms of implantation. Dev Reprod. 2017;21(4):351–9.
pubmed: 29359200 pmcid: 5769129 doi: 10.12717/DR.2017.21.4.351
Vitiello D, Patrizio P. Implantation and early embryonic development: implications for pregnancy. Semin Perinatol. 2007;31(4):204–7.
pubmed: 17825673 doi: 10.1053/j.semperi.2007.05.006
Teh WT, McBain J, Rogers P. What is the contribution of embryo-endometrial asynchrony to implantation failure? J Assist Reprod Genet. 2016;33(11):1419–30.
pubmed: 27480540 pmcid: 5125144 doi: 10.1007/s10815-016-0773-6
Sebastian-León P, Garrido N, Remohí J, Pellicer A, Diaz-Gimeno P. Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure. Hum Reprod. 2018;33:626–35.
pubmed: 29452422 doi: 10.1093/humrep/dey023
Coughlan C, Ledger W, Wang Q, Liu F, Demirol A, Gurgan T, Cutting R, Ong R, Sallam H, Li TC. Recurrent implantation failure: definition and management. Reprod BioMed Online. 2014;28(1):14–38.
pubmed: 24269084 doi: 10.1016/j.rbmo.2013.08.011
Zeyneloglu HB, Onalan G. Remedies for recurrent implantation failure. Semin Reprod Med. 2014;32(4):297–305.
pubmed: 24919029 doi: 10.1055/s-0034-1375182
Rinehart J. Recurrent implantation failure: definition. J Assist Reprod Genet. 2007;24(7):284–7.
pubmed: 17674185 pmcid: 3455006 doi: 10.1007/s10815-007-9147-4
Zohni KM, Gat I, Librach C. Recurrent implantation failure: a comprehensive review. Minerva Ginecol. 2016;68(6):653–67.
pubmed: 26982235
Somigliana E, Vigano P, Busnelli A, Paffoni A, Vegetti W, Vercellini P. Repeated implantation failure at the crossroad between statistics, clinics and over-diagnosis. Reprod Biomed Online. 2018;36(1):32–8.
pubmed: 29102484 doi: 10.1016/j.rbmo.2017.09.012
Thornhill AR, deDie-Smulders CE, Geraedts JP, Harper JC, Harton GL, Lavery SA, Moutou C, Robinson MD, Schmutzler AG, Scriven PN, et al. ESHRE PGD Consortium ‘Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).’ Hum Reprod. 2005;20:35–48.
pubmed: 15539444 doi: 10.1093/humrep/deh579
Bashiri A, Halper KI, Orvieto R. Recurrent implantation failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol. 2018;16(1):121–39.
pubmed: 30518389 pmcid: 6282265 doi: 10.1186/s12958-018-0414-2
Kliman HJ, Frankfurter D. Clinical approach to recurrent implantation failure: evidence-based evaluation of the endometrium. Fertil Steril. 2019;111(4):618–28.
pubmed: 30929719 doi: 10.1016/j.fertnstert.2019.02.011
Magdi Y, El-Damen A, Fathi AM, et al. Revisiting the management of recurrent implantation failure through freeze-all policy. Fertil Steril. 2017;108(1):72–7.
pubmed: 28579406 doi: 10.1016/j.fertnstert.2017.04.020
Moustafa S, Young SL. Diagnostic and therapeutic options in recurrent implantation failure [version 1; peer review: 2 approved]. F1000Research 2020; 9(F1000 Faculty Rev):208–217.
Altmäe S, Reimand JR, Hovatta O, Zhang P, Kere J, Laisk T, Saare M, Peters M, Vilo J, Stavreus-Evers A, et al. Research resource: interactome of human embryo implantation: identification of gene expression pathways, regulation, and integrated regulatory networks. Mol Endocrinol. 2012;26:203–17.
pubmed: 22074951 doi: 10.1210/me.2011-1196
Lessey B, Young S. What exactly is endometrial receptivity? Fertil Steril. 2019;111(4):611–7.
pubmed: 30929718 doi: 10.1016/j.fertnstert.2019.02.009
Dvořan M, Vodička J, Dostál J, Hajdúch M, Džubák P, Pešková M, Pilka R. Implantation and diagnostics of endometrial receptivity Implantace a diagnostika receptivity endometria. Ceska Gynekol. 2018;83(4):291–8.
pubmed: 30441961
Miravet-Valenciano JA, Rincon-Bertolin A, Vilella F, Simon C. Understanding and improving endometrial receptivity. Curr Opin Obstet Gynecol. 2015;27(3):187–92.
pubmed: 25827647 doi: 10.1097/GCO.0000000000000173
Paulson RJ. Introduction: endometrial receptivity: evaluation, induction and inhibition. Fertil Steril. 2019;111(4):609–10.
pubmed: 30929717 doi: 10.1016/j.fertnstert.2019.02.029
Cailleau J, Vermeire S, Verhoeven G. Independent control of the production of insulin-like growth factor I and its binding protein by cultured testicular cells. Mol Cell Endocrinol. 1990;69:79–89.
pubmed: 2157618 doi: 10.1016/0303-7207(90)90091-L
Altmäe S, Aghajanova L. Growth hormone and endometrial receptivity. Front Endocrinol (Lausanne). 2019;10:653–64.
pubmed: 31616379 doi: 10.3389/fendo.2019.00653
Liu FT, Wu Z, Yan J, Norman RJ, Li R. The potential role of growth hormone on the endometrium in assisted reproductive technology. Front Endocrinol (Lausanne). 2020;11:49–57.
pubmed: 32117072 doi: 10.3389/fendo.2020.00049
Cui N, Li AM, Luo ZY, Zhao ZM, Xu YM, Zhang J, Yang AM, Wang LL, Hao GM, Gao BL. Effects of growth hormone on pregnancy rates of patients with thin endometrium [published correction appears in J Endocrinol Invest. 2018 Aug 20]. J Endocrinol Invest. 2019;42(1):27–35.
Sbracia M, Scarpellini F, Poverini R, Alò PL, Rossi G, Di Tondo U. Immunohistochemical localization of the growth hormone in human endometrium and decidua. Am J Reprod Immunol. 2004;51:112–6.
pubmed: 14748836 doi: 10.1046/j.8755-8920.2003.00127.x
Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29(6):789–91.
pubmed: 19164810 doi: 10.1161/ATVBAHA.108.179663
Korompelis P, Piperi C, Adamopoulos C, Dalagiorgou G, Korkolopoulou P, Sepsa A, Antsaklis A, Papavassiliou AG. Expression of vascular endothelial factor-A, gelatinases (MMP-2, MMP-9) and TIMP-1 in uterine leiomyomas. Clin Chem Lab Med. 2015;53(9):1415–24.
pubmed: 25470608 doi: 10.1515/cclm-2014-0798
Popovici RM, Irwin JC, Giaccia AJ, Giudice LC. Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: potential relevance to menstruation and endometrial regeneration. J Clin Endocrinol Metab. 1999;84(6):2245–8.
pubmed: 10372740 doi: 10.1210/jcem.84.6.5886
Sun ZG, Lian F, Jia Q, Sun JL, Li TT, Guo Y, Zhang JW, Zhang N, Liu H, Wang LH. Effects of Er’zhi Tiangui Granule on sequential expressions of integrin β 3 and its ligand osteopontin in mouse endometrium during controlled ovarian hyperstimulation. Chin J Integr Med. 2012;18(11):846–9.
pubmed: 23086489 doi: 10.1007/s11655-012-1273-7
Tei C, Maruyama T, Kuji N, Miyazaki T, Mikami M, Yoshimura Y. Reduced expression of αvβ3 integrin in the endometrium of unexplained infertility patients with recurrent IVF-ET failures: improvement by danazol treatment. J Assist Reprod Genet. 2003;20:13–20.
pubmed: 12645863 pmcid: 3455802 doi: 10.1023/A:1021254620888
Lessey BA, Castelbaum AJ. Integrins and implantation in the human. Rev Endocr Metab Disord. 2002;3(2):107–17.
pubmed: 12007287 doi: 10.1023/A:1015450727580
Kaneko Y, Day ML, Murphy CR. Integrin β3 in rat blastocysts and epithelial cells is essential for implantation in vitro: studies with Ishikawa cells and small interfering RNA transfection. Hum Reprod. 2011;26(7):1665–74.
pubmed: 21531996 doi: 10.1093/humrep/der128
Taketani T, Yamagata Y, Takasaki A, Matsuoka A, Tamura H, Sugino N. Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells. Fertil Steril. 2008;90:744–8.
pubmed: 17953960 doi: 10.1016/j.fertnstert.2007.07.1304
Schams D, Berisha B, Kosmann M, Einspanier R, Amselgruber WM. Possible role of growth hormone, IGFs, and IGF-binding proteins in the regulation of ovarian function in large farm animals. Domest Anim Endocrinol. 1999;17:279–85.
pubmed: 10527130 doi: 10.1016/S0739-7240(99)00044-2
Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory systemin health and disease. Endocr Rev. 1999;20:535–82.
pubmed: 10453357 doi: 10.1210/edrv.20.4.0374
Eftekhar M, Aflatoonian A, Mohammadian F, Eftekhar T. Adjuvant growth hormone therapy in antagonist protocol in poor responders undergoing assisted reproductive technology. Arch Gynecol Obstet. 2013;287:1017–21.
pubmed: 23208461 doi: 10.1007/s00404-012-2655-1
Dakhly DMR, Bayoumi YA, Gad Allah SH. Which is the best IVF/ICSI protocol to be used in poor responders receiving growth hormone as an adjuvant treatment? A prospective randomized trial Gynecol Endocrinol. 2016;32:116–9.
pubmed: 26416521 doi: 10.3109/09513590.2015.1092136
Kucuk T, Kozinoglu H, Kaba A. Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. J Assist Reprod Genet. 2008;25:123–7.
pubmed: 18392675 pmcid: 2582075 doi: 10.1007/s10815-008-9212-7
Dakhly DMR, Bassiouny YA, Bayoumi YA, Hassan MA, Gouda HM, Hassan AA. The addition of growth hormone adjuvant therapy to the long down regulation protocol in poor responders undergoing in vitro fertilization: randomized control trial. Eur J Obstet Gynecol Reprod Biol. 2018;228:161–5.
pubmed: 29957401 doi: 10.1016/j.ejogrb.2018.06.035
Wu H, Li L, Li M, Yuan H. Effect of growth hormone on the endometrial and endometrial blood flow in forzen thawed embryo tranfer. J Reprod Med. 2013;12:914–7.
Yu H, Gao S, Tang H, Chen H, Deng Z, Yang L, et al. Growth hormone intrauterine perfusion combined with replacement cycle in the treatment of non-response thin endometrium: report of 5 cases. Int J Clin Exp Med. 2016;9:11982–9.
Yang JY, Li H, Lu N, Li L, Sun XX. Influence of growth hormone supplementation in patients with thin endometrium undergoing frozen embryo transfer. Reprod Dev Med. 2019;3:49–53.
doi: 10.4103/2096-2924.255983
Lan KC, Lin PY, Chang YC, Chen YJ, Tsai YR, Mohamed ISI, Kang HY. Growth hormone supplementation may improve the pregnancy rate and endometrial receptivity among women aged more than 40 years undergoing in vitro fertilization. Biomed J. 2019;42(6):411–6.
pubmed: 31948605 pmcid: 6962760 doi: 10.1016/j.bj.2019.05.003
Choe SA, Kim MJ, Lee HJ, Kim J, Chang EM, Kim JW, Park HM, Lyu SW, Lee WS, Yoon TK, et al. Increased proportion of mature oocytes with sustained-release growth hormone treatment in poor responders: a prospective randomized controlled study. Arch Gynecol Obstet. 2018;297:791–6.
pubmed: 29264647 doi: 10.1007/s00404-017-4613-4
Coughlan C, Walters S, Ledger W, Li TC. A comparison of psychological stress among women with and without reproductive failure. Int J Gynaecol Obstet. 2014;124(2):143–7.
pubmed: 24290538 doi: 10.1016/j.ijgo.2013.08.006
Gameiro S, Boivin J, Peronace L, Verhaak CM. Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment. Hum Reprod Update. 2012;18(6):652–69.
pubmed: 22869759 pmcid: 3461967 doi: 10.1093/humupd/dms031
Gameiro S, Verhaak CM, Kremer JA, Boivin J. Why we should talk about compliance with assisted reproductive technologies (ART): a systematic review and meta-analysis of ART compliance rates. Hum Reprod Update. 2013;19(2):124–35.
pubmed: 23178304 doi: 10.1093/humupd/dms045
Busnelli A, Reschini M, Cardellicchio L, Vegetti W, Somigliana E, Vercellini P. How common is real repeated implantation failure? An indirect estimate of the prevalence. Reprod Biomed Online. 2020;40(1):91–7.
pubmed: 31924493 doi: 10.1016/j.rbmo.2019.10.014
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook .
Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15 Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726–35.
pubmed: 23570745 doi: 10.1016/j.jclinepi.2013.02.003
Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, Brignardello-Petersen R, Carrasco-Labra A, De Beer H, Hultcrantz M, et al. GRADE Working Group. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2020;119:126–35.
pubmed: 31711912 doi: 10.1016/j.jclinepi.2019.10.014
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
doi: 10.1136/bmj.39489.470347.AD
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
Altmäe S, Mendoza-Tesarik R, Mendoza C, Mendoza N, Cucinelli F, Tesarik J. Effect of growth hormone on uterine receptivity in women with repeated implantation failure in an oocyte donation program: a randomized controlled trial. J Endocr Soc. 2017;2(1):96–105.
pubmed: 29379897 pmcid: 5779111 doi: 10.1210/js.2017-00359
Chen Y, Liu F, Nong Y, Ruan J, Guo Q, Luo M, et al. Clinical efficacy and mechanism of growth hormone action in patients experiencing repeat implantation failure. Can J Physiol Pharmacol. 2018;96(9):929–32.
pubmed: 29726701 doi: 10.1139/cjpp-2017-0786
CORRIGENDUM FOR "Effect of growth hormone on uterine receptivity in women with repeated implantation failure in an oocyte donation program: a randomized controlled trial". J Endocr Soc. 2018;2(2):133.
Ethics Committee of the American Society for Reproductive Medicine. Oocyte or embryo donation to women of advanced age: a committee opinion. Fertil Steril. 2013;100(2):337–40.
doi: 10.1016/j.fertnstert.2013.02.030
Ethics Committee of the American Society for Reproductive Medicine. Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion. Fertil Steril. 2019;111(4):659–63.
doi: 10.1016/j.fertnstert.2019.01.033
MacArthur T, Bachmann G, Ayers C. Menopausal women requesting egg/embryo donation: examining health screening guidelines for assisted reproductive technology. Menopause. 2016;23(7):799–802.
pubmed: 27187010 doi: 10.1097/GME.0000000000000622
Somigliana E, Paffoni A, Busnelli A, Filippi F, Pagliardini L, Vigano P, Vercellini P. Age-related infertility and unexplained infertility: an intricate clinical dilemma. Hum Reprod. 2016;31(7):1390–6.
pubmed: 27060173 doi: 10.1093/humrep/dew066
Regan SLP, Knight PG, Yovich JL, Arfuso F, Dharmarajan A. Growth hormone during in vitro fertilization in older women modulates the density of receptors in granulosa cells, with improved pregnancy outcomes. Fertil Steril. 2018;110(7):1298–310.
pubmed: 30503129 doi: 10.1016/j.fertnstert.2018.08.018
Yu X, Ruan J, He LP, Hu W, Xu Q, Tang J, Jiang J, Han J, Peng YF. Efficacy of growth hormone supplementation with gonadotrophins in vitro fertilization for poor ovarian responders: an updated meta-analysis. Int J Clin Exp Med. 2015;8(4):4954–67.
pubmed: 26131068 pmcid: 4483949
Hart RJ. Use of growth hormone in the IVF treatment of women with poor ovarian reserve. Front Endocrinol (Lausanne). 2019;10:500–7.
pubmed: 31396160 doi: 10.3389/fendo.2019.00500
Hart RJ, Rombauts L, Norman RJ. Growth hormone in IVF cycles: any hope? Curr Opin Obstet Gynecol. 2017;29(3):119–25.
pubmed: 28306560 doi: 10.1097/GCO.0000000000000360
Duffy JM, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database Syst Rev. 2010;2010(1):CD000099.
Zhang Y, Zhang C, Shu J, Guo J, Chang HM, Leung PCK, Sheng JZ, Huang H. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update. 2020;26(2):247–63.
pubmed: 32045470 doi: 10.1093/humupd/dmz046
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ; GRADE Working Group. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336(7651):995–998.
Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ. GRADE Working Group. Going from evidence to recommendations BMJ. 2008;336(7652):1049–51.
pubmed: 18467413

Auteurs

Maira Vera-Montoya (M)

Health Sciences Faculty, Universidad del Cauca, Popayan, Colombia.
Post-Graduation Center, Women's Health, Medicine Faculty, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Jose Andrés Calvache (J)

Health Sciences Faculty, Universidad del Cauca, Popayan, Colombia. jacalvache@unicauca.edu.co.
Erasmus University Medical Center, Rotterdam, The Netherlands. jacalvache@unicauca.edu.co.

Selmo Geber (S)

Post-Graduation Center, Women's Health, Medicine Faculty, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH